ArticleHepatology research : the official journal of the Japan Society of Hepatology2015
Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review.
Article in Hepatology research : the official journal of the Japan Society of Hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02642185 (Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases), which is not on this map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases
Who cites it
45 citing papers in PubMed.
- Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.Cancer science · 2020Trial
- Comparable and Complimentary Modalities for Treatment of Small-Sized HCC: Surgical Resection, Radiofrequency Ablation, and Microwave Ablation.Journal of clinical medicine · 2023Review
- NIMA-related kinase 6 as an effective target inhibits the hepatocarcinogenesis and progression of hepatocellular carcinoma.Heliyon · 2023Article
- Elevated intramuscular adipose tissue content with a high Ishak fibrosis stage (>3) had a negative effect on liver regeneration in cirrhotic patients undergoing portal vein embolization.The Kaohsiung journal of medical sciences · 2023Article
- Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells.Cellular & molecular biology letters · 2021Review
- HBx promotes hepatocarcinogenesis by enhancing phosphorylation and blocking ubiquitinylation of UHRF2.Hepatology international · 2021Article
- Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.Digestive diseases and sciences · 2021Article
- Sarcopenia and Frailty in Liver Cirrhosis.Life (Basel, Switzerland) · 2021Review
- The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.Journal of gastroenterology · 2021Article
- S100 Calcium Binding Protein A10, A Novel Oncogene, Promotes the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma.Frontiers in genetics · 2021Article
- lncRNA KCNQ1OT1 reverses the effect of sevoflurane on hepatocellular carcinoma progression via regulating the miR-29a-3p/CBX3 axis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- Percutaneous radiofrequency ablation is superior to hepatic resection in patients with small hepatocellular carcinoma.World journal of clinical cases · 2020Article
- The perplexity of targeting genetic alterations in hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2020Article
- Anthropometric Measurements and Frailty in Patients with Liver Diseases.Diagnostics (Basel, Switzerland) · 2020Article
- Transition in the etiology of liver cirrhosis in Japan: a nationwide survey.Journal of gastroenterology · 2020Article
- Serum Zinc Level Grading System: A Useful Model for Composite Hepatic Events in Hepatitis C Virus-Associated Liver Cirrhosis.Journal of clinical medicine · 2020Article
- SRC-1 and Twist1 are prognostic indicators of liver cancer and are associated with cell viability, invasion, migration and epithelial-mesenchymal transformation of hepatocellular carcinoma cells.Translational cancer research · 2020Article
- Waist Circumference and Risk of Liver Cancer: A Systematic Review and Meta-Analysis of over 2 Million Cohort Study Participants.Liver cancer · 2020Review
- Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC.Journal for immunotherapy of cancer · 2019Article
- Serum Zinc Level Classification System: Usefulness in Patients with Liver Cirrhosis.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. In the last few decades, there has been a marked increase in therapeutic options for HCC and epidemiological characteristics at HCC diagnosis have also significantly changed. With these changes and advances in medical technology and surveillance program for detecting earlier stage HCC, survival in patients with HCC has significantly improved. Especially, patients with liver cirrhosis are at high risk of HCC development, and regular surveillance could enable early detection of HCC and curative therapy, with potentially improved clinical outcome. However, unfortunately, only 20% of HCC patients are amenable to curative therapy (liver transplantation, surgical resection or ablative therapies). Locoregional therapies such as radiofrequency ablation, percutaneous ethanol injection, microwave coagulation therapy and transcatheter arterial chemoembolization play a key role in the management of unresectable HCC. Currently, molecular-targeted agents such as sorafenib have emerged as a promising therapy for advanced HCC. The choice of the treatment modality depends on the size of the tumor, tumor location, anatomical considerations, number of tumors present and liver function. Furthermore, new promising therapies such as gene therapy and immunotherapy for HCC have emerged. Approaches to the HCC diagnosis and adequate management for patients with HCC are improving survival. Herein, we review changes of epidemiological characteristics, prognosis and therapies for HCC and refer to current knowledge for this malignancy based on our experience of approximately 4000 HCC cases over the last three decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.